FORMULATION AND EVALUATION OF TRANSDERMAL FILMS CONTAINING CELECOXIB INCLUSIONS FOR TREATING PSORIATIC ARTHRITIS
Objective: The main objective of the present work was to prepare and evaluate transdermal films and creams of celecoxib inclusions which are nonsteroidal anti-inflammatory drug to treat psoriatic arthritis.
Methods: Celecoxib inclusions were prepared using β-cyclodextrin to increase the solubility. These inclusions were incorporated in transdermal films. Hydroxy Propyl Methyl Cellulose (HPMC), dibutyl phthalate, propylene glycol, and glycerin were used to prepare the film. Fourier transform infrared and differential scanning calorimetry studies were carried out for pure celecoxib and inclusions. Morphological properties, weight variation, surface pH, percentage elongation, folding endurance, in vitro disintegration, and in vitro diffusion studies were carried out for films.
Results: All the results obtained were within the limits and confirmed the prolonged drug release and increased solubility of celecoxib inclusions.
Conclusion: From the results obtained, increase in solubility of celecoxib drug was confirmed by forming inclusions using β-CD as polymer.
2. Gladman DD, Antonic, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, outcome. Ann Rheum Dis 2005;64:ii14-7.
3. Carol MP. Pathophysiology: Concepts of Altered Health States. 7th ed. Lippincott Williams and Wilkins; 2004. p. 1428-9.
4. Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016;151:110-9.
5. Damini N, Aniruddha M, Bina KM, Sugato B. Metabolic syndrome associated complications. Int J Pharm Pharm Sci 2015;7(7):22-5.
6. Camilla F. Genetic Studies of Psoriasis and Psoriatic Arthritis. Department of Medical and Clinical Genetics, Institute of Biomedicine. Gothenburg, Sweden: The Sahlgrenska Academy at Goteborg University Sweden; 2007.
7. DoQuyen H, Arthur K. Psoriatic arthritis: Current therapy and future approaches. Rheumatology 2015;54:20-8.
8. Eun JK, Arthur K. Psoriatic arthritis: Latest treatments and their place in therapy. Ther Adv Chronic Dis 2015;l6:194-203.
9. Jayashree V, Prakash R. Protective effect of COX inhibitors on lipopolysaccharide induced sickness behaviour or neuroinflammation and oxidative stress on male Wistar rats. Int J Pharm Pharm Sci 2015;7(6):240-45.
10. Baskar R, Joseph RS, Rajesh M, Subramanian I, Palanichamy A Thangathirupathi A. Formulation and evaluation of celecoxib loaded nanosized emulsion as transdermal drug delivery vehicle. Int J Pharm Sci Res 2010;1:41-9.
11. Goyal A, Kumar S, Nagpal M, Singh I, Arora S. Potential of novel drug delivery systems for herbal drugs. Ind J Pharma Res Educ 2011;45:225-35.
12. Archer HK, Pettit MS. Analgesic and Antiphlogistic Compositions and Therapeutic Wrap for Topical Delivery. United States Patent No. 5976547.
13. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS Pharm Sci Tech 2007;8:2.
14. Deodr SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferyloyl methane). Indian J Med Res 1980;71:632-40.
15. Shikha A, Nidhi S, Narendra KJ, Agarwal GP. Solubility enhancement of poorly water soluble celecoxib for parenteral formulations. Int J Pharm Sci Res 2012;3:2325-36.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.